medigraphic.com
ISSN 1405-8871 (Print)

2013, Number 1

<< Back Next >>

Aten Fam 2013; 20 (1)

Prevalence of Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome

Zamora-Alvizo EL, Gómez-Gómez C, Muñoz-Espinosa LE, Martínez-Lazcano F, Ramírez-Aranda JM, Rodríguez-Garza CY

Language: Spanish
References: 21
Page: 16-20
PDF size: 287.58 Kb.


ABSTRACT

Objective: determine the prevalence of non-alcoholic steatohepatitis in adult patients with metabolic syndrome from the outpatient consultation of the University Hospital “Dr. José Eleuterio González” of the Autonomous University of Nuevo Leon, Mexico. Material and methods: patients with chronic degenerative diseases were selected and they were classified into two groups: Group 1 with metabolic syndrome, and group 2 without metabolic syndrome; they underwent laboratory tests, an upper abdomen ultrasound, and a FibroMax only those who presented a hepatic steatosis. Results: from the 71 studied patients, 55 were classified in Group 1; and 16 in Group 2; 42 of Group 1 and nine from Group 2 were diagnosed with steatosis. 18 Patients of Group 1 and two of Group 2 were diagnosed with non-alcoholic steatohepatitis. Conclusion: the prevalence of non-alcoholic steatohepatitis from this study was 25.3%, greater than the 4.5% reported by other researchers


REFERENCES

  1. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez- Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. 2009;15(3):280-8.

  2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95.

  3. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883-9.

  4. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res. 2005;33:68-71.

  5. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo experience with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.

  6. Caldwell SH, Oelsner DH, Lezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664-9.

  7. Tellez-Avila FI, Sanchez-Avila F, Garcia-Saenz-de- Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol. 2008;14:4771-5.

  8. Álvarez-Martínez HE, Pérez-Campos E, Leyva- Bohórquez P. Prevalencia de esteatohepatitis no alcohólica en pacientes con síndrome metabólico en Oaxaca. Gac Méd Méx. 2005;141(1):7-12.

  9. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-73.

  10. Nair S, Mason A, Eason J, Loss G, Perillo R. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36:150-5.

  11. Calle E, Rodriguez C, Walker-Thurmond K, Thun M. Overweight, obesity and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625-38.

  12. Angulo P. Nonalcoholic Fatty Liver Disease. N Engl J Med. 2002;346(16):1221-31.

  13. Práctica del FibroMax para la esteatosis y la esteatohepatitis de origen no alcohólico [Internet]. París, Francia. Disponible en: http://www.biopredictive. com/intl/physician/fibromax-for-metabolic

  14. Olaiz G, Rivera J, Shamah T, Rojas R, Villalpando S, Hernández M, et al. Encuesta Nacional de Salud y Nutrición. México: Instituto Nacional de Salud Pública-Secretaría de Salud, 2006.

  15. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997;126:137-45.

  16. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc. 2000;75:733-9.

  17. Chavin KD, Yang S, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem. 1999;274(9):5692-700.

  18. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrosis. Hepatology. 2002;35(6):1485-93.

  19. Lizardi-Cervera J, Laparra DI, Chávez-Tapia NC, Ostos ME, Esquivel MU. Prevalencia de hígado graso no alcohólico y síndrome metabólico en población asintomática. Rev Gastroenterol Mex. 2006;71(4):453-9.

  20. Bernal-Reyes R, Sáenz-Labra A, Bernardo-Escudero R. Prevalencia de la esteatohepatitis no alcohólica (EHNA). Estudio comparativo con diabéticos. Gastroenterol Mex. 2000;65:58-62.

  21. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129:375-8.




2020     |     www.medigraphic.com